generic speaker image
Celine Moore, PhD - Canadian Partnership Against Cancer. Toronto, ON, CA

Celine Moore, PhD

Director, Data Linkage and Research | Canadian Partnership Against Cancer

Toronto, ON, CANADA

Leads the Canadian Partnership for Tomorrow Project, Canada’s largest health database involving more than 300,000 participants



Dr. Céline Moore is the Director of Data Linkage and Research at the Canadian Partnership Against Cancer.

Dr. Moore is also director of the Canadian Partnership for Tomorrow Project (CPTP) at the Canadian Partnership Against Cancer. In this role she provides leadership and management to the national coordination of CPTP.

Dr. Moore has 20 years of experience working in the biotechnology sector. Most recently, she was Chief Operating Officer and Vice President of Legal Affairs at Viventia Biotechnologies, Inc., a biopharmaceutical company specializing in the discovery and development of products that support safer cancer therapies. In that capacity, she was responsible for clinical and regulatory affairs, as well as: finance, intellectual property, contracts, licensing, administrative support, communications and information technology. Prior to this, she held management positions first in research and development and subsequently in intellectual property in the field of blood substitutes.

Dr. Moore holds a PhD in Endocrinology, Cell Biology and Immunology from Dalhousie University and did her Postdoctoral research at Texas Tech University. She also holds a Master's of Science in reproductive endocrinology from McGill University.

Areas of Expertise (12)

Health Data Harmonization of Health Data Population Health Research Drug Development Clinical Development Biotechnology Pharmaceutical Industry Monoclonal Antibodies Life Sciences Protein Chemistry Intellectual Property Contracts and Licensing

Education (4)

Texas Tech University Health Sciences Center - School of Medicine: Postdoctoral Fellowship, Cellular Physiology 1993

Dalhousie University: PhD, Physiology and Biophysics (Endocrinology) 1990

McGill University: MSc, Reproductive Endocrinology

McGill University: BSc, Animal Science

Languages (2)

  • English
  • French

Media Appearances (1)

Cancer colorectal: faible taux de dépistage au Québec

Le Devoir  print


Le taux de dépistage du cancer colorectal est plus faible au Québec que partout ailleurs au Canada. Voilà un des constats figurant dans le rapport 2014 sur le rendement du système de lutte contre le cancer, publié mercredi par le Partenariat canadien contre le cancer en collaboration avec les programmes provinciaux de lutte contre le cancer.

Bien qu’il se soit accru de 12 % depuis 2008, le taux de dépistage du cancer colorectal par examen coloscopique demeure faible au Québec (28,3 %). Selon Céline Moore, l’une des directrices du Partenariat, ce retard s’expliquerait en partie par le fait que «les autres provinces ont commencé plus tôt que le Québec à instaurer un programme de dépistage pour ce cancer», qui est la deuxième cause de décès par cancer tant chez les hommes que chez les femmes.

view more

Articles (2)

Rationale, design, and methods for Canadian alliance for healthy hearts and minds cohort study (CAHHM) – a Pan Canadian cohort study BMC Public Health


The Canadian Alliance for Healthy Hearts and Minds (CAHHM) is a pan-Canadian, prospective, multi-ethnic cohort study being conducted in Canada. The overarching objective of the CAHHM is to understand the association of socio-environmental and contextual factors (such as societal structure, activity, nutrition, social and tobacco environments, and access to health services) with cardiovascular risk factors, subclinical vascular disease, and cardiovascular and other chronic disease outcomes.

view more

A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin The Journal of Urology


A phase II study was performed to assess the efficacy and tolerability of intravesical oportuzumab monatox in patients with urothelial carcinoma in situ of the bladder. Bacillus Calmette-Guérin treatment had previously failed in all patients.

view more